
Nicaragua

Honduras El Salvador Confirmed Pf cases p 1000 population 0 0-0.1 0.1-1 1-10 10-50 50-100 > 100 > 100 insufficient dat Costa Rica



I. Epidemiological profile

Reported deaths:


Population (UN Population Division)	2017	%
High transmission (>1 case per 1000 population)	533.7K	9
Low transmission (0-1 case per 1000 population)	2.2M	35
Malaria free (0 cases)	3.5M	56
Total	6.2M	
Reported cases and deaths		
Reported confirmed cases (health facility):	10	949
Confirmed cases at community level:		-
Confirmed cases from private sector:		-


7 %	Parasites and vectors	
. 9	Major plasmodium species:	P.falciparum: 17 (%) , P.vivax: 82 (%)
I 35	Major anopheles species:	An. albimanus, An. pseudopunctipennis
1 56		
1		
	Estimates	
0 949	Estimated cases:	13.7K [11.5K, 16.1K]
-		
-		
-	Estimated deaths:	10 [2, 17]


II. Intervention policies and strategies


	-		
Intervention	Policies/Strategies	Yes/	Year
		No	adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2004
	ITNs/LLINs distributed to all age groups	Yes	2016
IRS	IRS is recommended	Yes	1959
	DDT is used for IRS	No	-
Larval control	Use of Larval Control	Yes	
IPT	IPT used to prevent malaria during pregnancy	NA	-
Diagnosis Patients of all ages should receive diagnostic test	Yes	2014	
	Malaria diagnosis is free of charge in the public sector	Yes	-
Treatment	ACT is free for all ages in public sector	Yes	1980
		has	
	The sale of oral artemisinin-based monotherapies (oAMTs)	never	-
		been	
		allowed	
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	Yes	1980
	Primaquine is used for radical treatment of P. vivax	Yes	2014
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	1980
	System for monitoring of adverse reaction to antimalarials exists	Yes	2011
Surveillance	ACD for case investigation (reactive)	Yes	-
	ACD at community level of febrile cases (pro-active)	Yes	-
	Mass screening is undertaken	No	-
	Uncomplicated P. falciparum cases routinely admitted	No	-
	Uncomplicated P. vivax cases routinely admitted	No	-
	Case and foci investigation undertaken Case reporting from private sector is mandatory	Yes	2017
	· - · /		

Antimalaria treatme	nt policy			Medicine	Year adopted	
First-line treatment		ed malaria		-	-	
First-line treatment	of P. falciparu	im		CQ+PQ(1d)	-	
For treatment failure of P. falciparum Treatment of severe malaria			AS+MQ; AS+SP	-		
			QN	-		
Treatment of P. viva	х			CQ+PQ(7d)	-	
Dosage of primagui	ne for radical	treatment of	P. vivax	0.5	50 mg/Kg (7 days	
Type of RDT used				P.f + P.v specific (Combo)		
Therapeutic efficacy	/ tests (clinical	l and parasito	ological failure,	%)		
Medicine Year	Min Med	ian Max	Follow-up	No. of studies	Species	
Resistance status by	/ insecticide cl	ass (2010-20	117) and use of c	class for malaria vector	control (2017)	
Insecticide class	Years	(%) sites ¹	Vectors ²		Used ³	
Carbamates	2010-2013	12.5% (8)	An. pseudopunctipennis		No	
Organochlorines	-	-			No	
Organophosphates	2011-2011	0% (4)	-		No	
organophosphates				A		
Pyrethroids	2010-2016	4.76% (42)	An. albimanus, J	An. pseudopunctipennis	Yes	
Pyrethroids		_ ``			Yes	
5 1 1	ich resistance con	firmed and tota			Yes	











Government expenditure by intervention in 2017





World Malaria Report 2018